2017 Access to Vaccines Index
Monday, 6 March 2017
The first landscape analysis showing how vaccine company are responding to calls to increase access to vaccines.
The Access to Vaccines Index is an independent initiative that has mapped how vaccine companies are responding to global calls to increase immunisation coverage.
Vaccines are one of the most powerful and cost effective health interventions available. Yet preventable diseases still cost millions of lives each year. Vaccine companies are a key link in the chain to each successful vaccination.
For the first time, the Access to Vaccines Index has mapped how vaccine companies are responding to global calls to increase immunisation coverage. It finds that the eight companies measured approach access to vaccines in differing ways, generally linked to whether their businesses are focused more on developing new vaccines or on marketing existing ones, or on both.
The Index has compared key characteristics of each company included in the Index scope. The companies evaluated in the Access to Vaccines Index have diverse business models, which are reflected in their vaccine pipelines, portfolios, revenues and number of doses sold globally.
The industry is highly consolidated: the “big four” – GSK, Merck & Co., Inc., Pfizer and Sanofi – represent a large proportion (around 80%) of global vaccine revenues. While all companies within this group have very high vaccine revenues, there are also important differences between them: GSK and Sanofi have a large number of vaccines in their diverse portfolios, a relatively wide geographic spread and larger-than-average pipelines. Merck and Co., Inc. and Pfizer have smaller pipelines and portfolios, and sell fewer doses globally.